Guangdong Taienkang Pharmaceutical Co., Ltd. Class A

Guangdong Taienkang Pharmaceutical Co., Ltd. Class A

SSZSE:301263
17.75
CNY
-0.24
(-1.33%)
0.02EPS
333.72P/E
9.75BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.92
1.04
1.17
1.1
1.32
1.53
1.46
1.98
1.71
1.65
1.5
1.44
1.37
1.36
Basic EPS, GAAP
0.33
0.14
0.13
0.08
0.16
0.22
0.16
0.45
0.31
0.37
0.32
0.22
0.06
0.06
Free Cash Flow per Basic Share
0.05
0.06
-0.09
-0.09
-0.02
0.12
0.2
0.09
0.2
0.12
-0.21
0.04
-0.25
- -
Dividend per Share
0.14
0.14
0.08
0.05
0.01
0.02
0.24
0.19
0.01
0.18
0.33
0.27
0.19
0.06
Book Value per Share
1.13
1.01
2.46
1.16
1.32
1.55
1.48
1.54
1.85
3.63
3.51
3.46
3.27
2.93
Tangible Book Value per Share
1.04
0.93
1.9
0.92
1.08
1.3
1.24
1.32
1.61
3.4
2.57
2.38
2
1.6
Basic Weighted Avg Shares
146
291
315
332
340
335
339
358
381
476
506
499
491
502
Sales/Revenue/Turnover
280
304
370
367
450
514
496
709
654
783
761
721
675
682
Operating Margin (%)
23.14
19.03
16.51
8.69
13.18
20.49
14.19
29.47
22.18
25.61
25.09
15.98
1.95
0.1
Depreciation Expense
3
4
9
13
15
17
19
23
28
33
39
54
66
- -
Net Income, GAAP
48
40
42
28
55
74
55
161
120
175
160
108
29
29
Effective Tax Rate (%)
26.06
26.81
29.63
33.86
21.08
20.39
19.89
22.2
12.76
15.79
20.19
8.08
- -
- -
Profit Margin (%)
17.16
13.33
11.44
7.54
12.26
14.49
11.06
22.68
18.37
22.29
21.06
15.01
4.24
4.21
Working Capital
128
110
191
163
180
241
213
257
339
1,377
934
767
631
342
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
- -
2
109
85
81
212
Total Equity
190
170
415
392
442
522
498
590
710
1,854
1,829
1,816
1,741
1,556
Return on Invested Capital (%)
25.82
20.04
10.78
3.72
9.2
14.1
9.36
24.44
15.98
12.87
7.72
4.87
- -
- -
Return on Capital (%)
26.26
20.85
13.56
7.43
13.22
16.56
12.87
28.48
16.71
13.12
8.67
6.27
- -
- -
Return on Common Equity (%)
27.37
22.49
14.53
6.91
13.22
15.45
10.81
29.62
18.48
13.62
8.79
6.08
1.67
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
287
332
391
LT Borrowings
70
63
210
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
511
511
511
Market Capitalization
10,995
10,462
9,747

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,179
1,109
1,080
Cash, Cash Equivalents & STI
577
643
573
Accounts Receivable, Net
343
279
305
Inventories
103
99
116
Total Current Liabilities
534
662
738
Payables & Accruals
- -
- -
- -
ST Debt
287
332
391
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.45%
35.08%
-4.14%
Free Cash Flow
-182.97%
-194.49%
-683.03%
Net Income, GAAP
17.21%
-18.83%
-73.54%
Sales/Revenue/Turnover
7.3%
-0.49%
-6.4%
Total Cash Common Dividend
320.51%
371.84%
-30.74%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
189
206
177
149
721
2025
185
162
- -
149
675
2026
190
131
212
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.08
0.06
-0.02
0.22
2025
0.06
0.01
- -
-0.01
0.06
2026
0.06
-0.05
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.25
- -
0.01
0.27
2025
- -
0.17
- -
- -
0.19
2026
0.01
0.05
0.01
- -
- -

Company Description

CEO
Han Jie Zheng
Full Time Employees
1,154
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Shantou China
IPO Date
Mar 29, 2022
Business
Guangdong Taienkang Pharmaceutical Co., Ltd. is a China-based pharmaceutical and healthcare enterprise engaged in the research, development, manufacturing, marketing, and distribution agency of pharmaceuticals, active pharmaceutical ingredients (APIs), and medical devices. Founded in 1999 and headquartered in Shantou, Guangdong Province, the company operates across four primary business divisions: Proprietary Pharmaceuticals, Traditional Chinese Medicine (TCM), Medical Devices and Consumables, and Pharmaceutical Agency and Commercialization Services. The company's core product and service portfolio comprises: sexual health and urology medications, including sildenafil citrate tablets (Eterda), tadalafil tablets (Eterway), dapoxetine hydrochloride tablets (Eterva), and combination finasteride and tadalafil capsules (Eterly); topical and dermatological formulations under the Wuhuan brand, including red flower oil, peppermint surface oil, compound ketoconazole cream, and external therapeutic ointments; ophthalmology and internal medicine treatments, including lecithin-bound iodine tablets (Woliting/Jolethin); Traditional Chinese Medicine preparations, including Hewei Zhengchang pills, Compound Black Chicken pills, Liuwei Dihuang pills, Xiaoyao pills, and the Tianfukang product line; medical consumables, including surgical and protective face masks, medical protective equipment, and in vitro diagnostic reagents; and agency distribution services providing comprehensive supply chain, regulatory management, and marketing channel access for domestic and international medical device and pharmaceutical manufacturers, including Johnson & Johnson. Taienkang distributes its products to hospitals, clinical centers, and retail pharmacy networks across more than 28 provinces in mainland China. The company operates through subsidiaries including Shandong Huabo Kaisheng Biotechnology Co., Ltd., Jiangsu Bochuangyuan Pharmaceutical Co., Ltd., Sichuan Taienkang Pharmaceutical Co., Ltd., Shantou Wuhuan Pharmaceutical Factory Co., Ltd., and Ma'anshan Tianfukang Pharmaceutical Co., Ltd. In recent developments, Taienkang acquired a controlling majority stake in Jiangsu Bochuangyuan Pharmaceutical Co., Ltd., expanding its innovative drug pipeline with CKBA (3-O-acetyl-11-keto-beta-boswellic acid ointment), a first-in-class small-molecule candidate undergoing Phase II and Phase III clinical development for vitiligo, rosacea, and psoriasis. The company has also advanced its pipeline of improved drug formulations, progressing clinical trials for cisplatin polymer micelles for solid tumors and pilocarpine hydrochloride ophthalmic drops for presbyopia. Furthermore, Taienkang entered strategic cooperation discussions to integrate artificial intelligence into its drug discovery processes for oncology and autoimmune diseases, while expanding its production capacity through the construction and upgrading of active pharmaceutical ingredient workshops and finished dosage manufacturing facilities across Anhui, Sichuan, and Guangdong.